U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07063875) titled 'Adding IL-2 to Tebentafusp to Eradicate Cancer Progression' on June 17.
Brief Summary: A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness.
This study aims to answer:
1. Can combining tebentafusp with IL-2 improve tumor response and overall survival?
2. What are the benefits and side effects of this combinat...